Inaticabtagene Autoleucel
- Generic Name
- Inaticabtagene Autoleucel
- Drug Type
- Biotech
- Indication
用于治疗成人复发或难治性B细胞急性淋巴细胞白血病(r/r B-ALL)。
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Phase 1
Not yet recruiting
- Conditions
- Autoimmune Thrombocytopenia
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06826430
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Phase 2
Recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-05
- Target Recruit Count
- 20
- Registration Number
- NCT06608732
- Locations
- 🇨🇳
National Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Early Phase 1
Recruiting
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06316791
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1
Recruiting
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT05667506
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Juventas Cell Therapy Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04586478
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳SunYat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Xinqiao Hospital of TMMU, Chongqing, Chongqing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath